Business
Notice of 2023 Annual General Meeting
Notice of 2023 Annual General Meeting.
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n\n\n \n \nAllergy Therapeutics plc\n(\"Allergy Therapeutics\" or the \"Company\")\n \nNotice of 2023 Annual General Meeting\n \n09 February 2024 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has today published its Notice of 2023 Annual General Meeting. It is available electronically on the Company's website at https://www.allergytherapeutics.com/investors/shareholder-services/agm-information/.\n \nA hard copy of the Notice of Meeting has been posted to shareholders on 9 February 2024.\n \n- ENDS -\n \nFor further information, please contact:\n \nAllergy Therapeutics\n+44 (0) 1903 845 820\nManuel Llobet, Chief Executive Officer\nShaun Furlong, Chief Financial Officer\n \nPanmure Gordon (Nominated Adviser and Broker)\n+44 (0) 20 7886 2500\nFreddy Crossley, Emma Earl, Corporate Finance\nRupert Dearden, Corporate Broking\n \nICR Consilium\n+44 20 3709 5700\nMary-Jane Elliott / David Daley / Davide Salvi\[email protected]\n \n \nNotes for editors:\n \nAbout Allergy Therapeutics\n \nAllergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree, house dust mite and peanut. For more information, please see www.allergytherapeutics.com.\n \n\n","length":4876,"tagName":"div"}]